Gdf-15 and Soluble St2 As Biomarkers of Right Ventricular Dysfunction in Pulmonary Hypertension

References

• Vonk-Noordegraaf A , HaddadF, ChinKMet al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J. Am. Coll. Cardiol.62(Suppl. 25), D22–D33 (2013).
   PubMed Web of Science ®Google Scholar
• Ghio S , KlersyC, MagriniGet al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int. J. Cardiol.140(3), 272–278 (2010).
   PubMed Web of Science ®Google Scholar
• Raymond RJ , HinderliterAL, WillisPWet al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J. Am. Coll. Cardiol.39(7), 1214–1219 (2002).
   PubMed Web of Science ®Google Scholar
• Sachdev A , VillarragaHR, FrantzRPet al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest139(6), 1299–1309 (2011).
   PubMed Web of Science ®Google Scholar
• Naeije R , ManesA. The right ventricle in pulmonary arterial hypertension. Eur. Respir. Rev.23(134), 476–487 (2014).
   PubMedGoogle Scholar
• Noordegraaf AV , WesterhofBE, WesterhofN. The relationship between the right ventricle and its load in pulmonary hypertension. J. Am. Coll. Cardiol.69, 236–243 (2017).
   PubMed Web of Science ®Google Scholar
• Petretta M , ColaoA, SarduCet al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm. IGF Res.17(4), 288–296 (2007).
   PubMed Web of Science ®Google Scholar
• Humbert M , KovacsG, HoeperMMet al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J.43(38), 3618–3731 (2022).
   PubMed Web of Science ®Google Scholar
• Aimo A , JanuzziJLJr, Bayes-GenisAet al. Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week. J. Am. Coll. Cardiol.74(17), 2193–2203 (2019).
   PubMed Web of Science ®Google Scholar
• Weinberg EO , ShimpoM, DeKeulenaer GWet al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation106(23), 2961–2966 (2002).
   PubMed Web of Science ®Google Scholar
• Sanada S , HakunoD, HigginsLJ, SchreiterER, MckenzieAN, LeeRT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest.117(6), 1538–1549 (2007).
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA , JanuzziJL. The biology of ST2: the International ST2 Consensus Panel. Am. J. Cardiol.115(Suppl. 7), 3b–7b (2015).
   PubMed Web of Science ®Google Scholar
• Seki K , SanadaS, KudinovaAYet al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ. Heart Fail.2(6), 684–691 (2009).
   PubMed Web of Science ®Google Scholar
• Ky B , FrenchB, MccloskeyKet al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail.4(2), 180–187 (2011).
   PubMed Web of Science ®Google Scholar
• Aimo A , VergaroG, PassinoCet al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail.5(4), 280–286 (2017).
   PubMed Web of Science ®Google Scholar
• Miller WL , SaengerAK, GrillDE, SlusserJP, Bayes-GenisA, JaffeAS. Prognostic value of serial measurements of soluble suppression of tumorigenicity 2 and galectin-3 in ambulatory patients with chronic heart failure. J. Card. Fail.22(4), 249–255 (2016).
   PubMed Web of Science ®Google Scholar
• Emdin M , AimoA, VergaroGet al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J. Am. Coll. Cardiol.72(19), 2309–2320 (2018).
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA , Bayes-GenisA, Asensio-LopezMCet al. The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure. J. Am. Coll. Cardiol.73(9), 1016–1025 (2019).
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA , Manzano-FernandezS, BoronatMet al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur. J. Heart Fail.13(7), 718–725 (2011).
   PubMed Web of Science ®Google Scholar
• Sardu C , MarfellaR, SantamariaMet al. Stretch, injury and inflammation markers evaluation to predict clinical outcomes after implantable cardioverter defibrillator therapy in heart failure patients with metabolic syndrome. Front. Physiol.9, 758 (2018).
   PubMed Web of Science ®Google Scholar
• Parikh RH , SeligerSL, ChristensonR, GottdienerJS, PsatyBM, DefilippiCR. Soluble ST2 for Prediction of heart failure and cardiovascular death in an elderly, community-dwelling population. J. Am. Heart Assoc.5(8), e003188 (2016).
   PubMed Web of Science ®Google Scholar
• Zimmers TA , JinX, HsiaoEC, McgrathSA, EsquelaAF, KoniarisLG. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock23(6), 543–548 (2005).
   PubMed Web of Science ®Google Scholar
• Kempf T , EdenM, StrelauJet al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ. Res.98(3), 351–360 (2006).
   PubMed Web of Science ®Google Scholar
• Mueller T , LeitnerI, EggerM, HaltmayerM, DieplingerB. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin. Chim. Acta445, 155–160 (2015).
   PubMed Web of Science ®Google Scholar
• Sharma A , StevensSR, LucasJet al. Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study. JACC Heart Fail.5(10), 724–734 (2017).
   PubMed Web of Science ®Google Scholar
• Lindholm D , JamesSK, GabryschKet al. Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study. JAMA Cardiol.3(12), 1160–1166 (2018).
   PubMed Web of Science ®Google Scholar
• Carlomagno G , MessalliG, MelilloRMet al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int. J. Cardiol.168(2), 1545–1547 (2013).
   PubMed Web of Science ®Google Scholar
• Zheng Y-G , YangT, HeJ-Get al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin. Cardiol.37(6), 365–370 (2014).
   PubMed Web of Science ®Google Scholar
• Geenen LW , BaggenVJM, KaulingRMet al. The prognostic value of soluble ST2 in adults with pulmonary hypertension. J. Clin. Med.8(10), 1517 (2019).
   PubMed Web of Science ®Google Scholar
• Geenen LW , BaggenVJM, KaulingRMet al. Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension. Heart106(6), 467 (2020).
   PubMed Web of Science ®Google Scholar
• Lang RM , BadanoLP, Mor-AviVet al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr.28(1), 1–39.e14 (2015).
   PubMed Web of Science ®Google Scholar
• Guazzi M , BanderaF, PelisseroGet al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am. J. Physiol. Heart Circ. Physiol.305(9), H1373–1381 (2013).
   PubMed Web of Science ®Google Scholar
• Tello K , AxmannJ, GhofraniHAet al. Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int. J. Cardiol.266, 229–235 (2018).
   PubMed Web of Science ®Google Scholar
• Keranov S , DorrO, JafariLet al. Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodeling in pulmonary hypertension. Biomark. Med.15(12), 1021–1034 (2021).
   PubMed Web of Science ®Google Scholar
• Truong QA , JanuzziJL, SzymonifkaJet al. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm11(12), 2167–2175 (2014).
   PubMed Web of Science ®Google Scholar
• Wang TJ , WollertKC, LarsonMGet al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation126(13), 1596–1604 (2012).
   PubMed Web of Science ®Google Scholar
• Chen LQ , DeLemos JA, DasSR, AyersCR, RohatgiA. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin. Chem.59(3), 536–546 (2013).
   PubMed Web of Science ®Google Scholar
• Sardu C , PaolissoG, MarfellaR. Inflammatory related cardiovascular diseases: from molecular mechanisms to therapeutic targets. Curr. Pharm. Des.26(22), 2565–2573 (2020).
   PubMed Web of Science ®Google Scholar
• Defilippi C , DanielsLB, Bayes-GenisA. Structural heart disease and ST2: cross-sectional and longitudinal associations with echocardiography. Am. J. Cardiol.115(Suppl. 7), B59–B63 (2015).
   Web of Science ®Google Scholar
• Kriechbaum SD , WiedenrothCB, PetersKet al. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension. Biomarkers25(7), 578–586 (2020).
   PubMed Web of Science ®Google Scholar
• Zheng YG , YangT, HeJGet al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin. Cardiol.37(6), 365–370 (2014).
   PubMed Web of Science ®Google Scholar
• Tello K , WanJ, DalmerAet al. Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ. Cardiovasc. Imaging12(9), e009047 (2019).
   PubMed Web of Science ®Google Scholar
• Keranov S , HaenS, VietheerJet al. Application and validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio in patients with ischemic and non-ischemic cardiomyopathy. Diagnostics11(12), 2188 (2021).
   Web of Science ®Google Scholar
• Pascual-Figal DA , Perez-MartinezMT, Asensio-LopezMCet al. Pulmonary production of soluble ST2 in heart failure. Circ. Heart Fail.11(12), e005488 (2018).
   PubMed Web of Science ®Google Scholar
• Shao D , PerrosF, CaramoriGet al. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochem. Biophys. Res. Commun.451(1), 8–14 (2014).
   PubMed Web of Science ®Google Scholar
• Gall H , FelixJF, SchneckFKet al. The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups. J. Heart Lung Transplant.36(9), 957–967 (2017).
   PubMed Web of Science ®Google Scholar
• Unsicker K , SpittauB, KrieglsteinK. The multiple facets of the TGF- β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev.24(4), 373–384 (2013).
   PubMed Web of Science ®Google Scholar
• Geenen LW , BaggenVJM, KaulingRMet al. Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension. Heart106(6), 467–473 (2020).
   PubMed Web of Science ®Google Scholar
• Luo JW , DuanWH, SongL, YuYQ, ShiDZ. A meta-analysis of growth differentiation factor-15 and prognosis in chronic heart failure. Front. Cardiovasc. Med.8, 630818 (2021).
   PubMed Web of Science ®Google Scholar
• Nickel N , KempfT, TapkenHet al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.178(5), 534–541 (2008).
   PubMed Web of Science ®Google Scholar
• Sardu C , PaolissoP, SacraCet al. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovasc. Diabetol.17(1), 137 (2018).
   PubMedGoogle Scholar
• Marfella R , SarduC, BalestrieriMLet al. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. Diabetol. Metab. Syndr.10, 1 (2018).
   PubMed Web of Science ®Google Scholar
• Paolisso P , BergamaschiL, SantulliGet al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc. Diabetol.21(1), 77 (2022).
   PubMed Web of Science ®Google Scholar